DeepMed Research

GE MEDICAL SYSTEMS

🇫🇷France

Country: 🇫🇷France

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Flurpiridaz (18F) Injection for PET Imaging for Assessment of MPI Quality Using HPLC and SPE Manufacturing Processes

Phase 2

Completed

Conditions: Ischemic Heart Disease
Coronary Artery Disease (CAD)

Interventions: Drug: Flurpiridaz (18F) Injection

First Posted Date: 2020-10-20

Last Posted Date: 2023-08-01

Lead Sponsor: GE Healthcare

Target Recruit Count: 38

Registration Number: NCT04594941

Locations: 🇺🇸
Memorial City and Katy Cardiology Associates, Katy, Texas, United States
🇺🇸
Amavita Clinical Research, LLC, North Miami Beach, Florida, United States
🇺🇸
University of Tennessee Medical Center, Knoxville, Tennessee, United States

and more 2 locations

A Study to Evaluate the Safety, Biodistribution, Internal Radiation Dosimetry, and Effective Dose of DaTSCAN™ Ioflupane (123I) Injection in Chinese Healthy Volunteers.

Phase 1

Completed

Conditions: Healthy Subjects (HS)

Interventions: Drug: DaTSCAN™ Ioflupane (123I) Injection

First Posted Date: 2020-09-25

Last Posted Date: 2023-08-02

Lead Sponsor: GE Healthcare

Target Recruit Count: 9

Registration Number: NCT04564092

Locations: 🇨🇳
Rujin hospital, affiliated to Shanghai Jiaotong University, School of Medicine, Huangpu, Shanghai, China

AMS Evaluation Study

Not Applicable

Completed

Conditions: Patient Monitoring

Interventions: Device: Ambulatory monitoring solution

First Posted Date: 2020-07-15

Last Posted Date: 2021-11-03

Lead Sponsor: GE Healthcare

Target Recruit Count: 34

Registration Number: NCT04472208

Locations: 🇬🇧
Chelsea and Westminster Hospital, London, United Kingdom

A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients

Phase 3

Completed

Conditions: Parkinsonian Syndrome
Progressive Supranuclear Palsy (PSP)
Essential Tremor
Parkinson Disease(PD)
Multiple System Atrophy (MSA)

Interventions: Drug: DaTSCAN™ Ioflupane (123I) Injection

First Posted Date: 2019-12-10

Last Posted Date: 2023-10-16

Lead Sponsor: GE Healthcare

Target Recruit Count: 172

Registration Number: NCT04193527

Locations: 🇨🇳
Nanfang Hospital, Nanfang Medical Univeristy, Guangdong, Guangzhou, China
🇨🇳
Beijing Anzhen Hospital, Capital Medical University, Beijing, Chaoyang District, China
🇨🇳
Peking Union Medical College Hospital, Beijing, Dongcheng District, China

and more 7 locations

Venue Ultrasound Evaluation - Israel

Not Applicable

Completed

Conditions: Ultrasound Exam in Emergency/Medical Care

Interventions: Device: Ultrasound

First Posted Date: 2019-03-04

Last Posted Date: 2019-03-04

Lead Sponsor: GE Healthcare

Target Recruit Count: 53

Registration Number: NCT03861663

Locations: 🇮🇱
Rambam Health Care Center, Haifa, Israel

Use of Digital Tomosynthesis for Detection and Case Management of Scaphoid and Distal Radius Fractures: A VolumeRAD Data Collection Study

Not Applicable

Conditions: Distal Radius Fracture
Scaphoid Fracture

Interventions: Device: DTS
Device: X-ray
Device: MRI or CT

First Posted Date: 2019-02-27

Last Posted Date: 2020-09-30

Lead Sponsor: GE Healthcare

Target Recruit Count: 140

Registration Number: NCT03856450

Locations: 🇺🇸
University of Pennsylvania Hospital - Department of Orthopaedic Surgery, Philadelphia, Pennsylvania, United States

Study to Determine Safety and Dosage of OPTISON in Pediatric Participants

Phase 4

Completed

Conditions: Transthoracic Echocardiography
Suspected or Known Structural or Functional Cardiac Abnormality

Interventions: Drug: Optison

First Posted Date: 2018-11-14

Last Posted Date: 2024-05-17

Lead Sponsor: GE Healthcare

Target Recruit Count: 39

Registration Number: NCT03740997

Locations: 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States

and more 5 locations

Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium

Completed

Conditions: ST-segment Elevation Myocardial Infarction
Coronary Artery Disease

Interventions: Drug: Iodixanol

First Posted Date: 2018-09-14

Last Posted Date: 2022-01-11

Lead Sponsor: GE Healthcare

Target Recruit Count: 2755

Registration Number: NCT03671603

Locations: 🇨🇳
Dongguan Kanghua Hospital, Guangdong, Guangdong, China
🇨🇳
Wuhan Asia Heart Hospital, Wuhan, Hubei, China
🇨🇳
China-Japan Friendship Hospital of Jilin University, Changchun, Jilin, China

and more 33 locations

Clinical Evaluation of the Next Generation Venue Ultrasound System, Components, and Accessories - Canada

Not Applicable

Completed

Conditions: Ultrasound Use in Emergency/Medical Care

Interventions: Device: Ultrasound exam

First Posted Date: 2018-08-31

Last Posted Date: 2018-08-31

Lead Sponsor: GE Healthcare

Target Recruit Count: 35

Registration Number: NCT03653572

Locations: 🇨🇦
Hopital Notre-Dame, Montréal, Quebec, Canada

Pediatric Risk of Hypothyroidism With Iodinated Contrast Media

Phase 4

Withdrawn

Conditions: Hypothyroidism

Interventions: Drug: Iohexol
Drug: Iodixanol
Drug: Iopromide
Drug: Ioversol

First Posted Date: 2018-08-15

Last Posted Date: 2022-04-20

Lead Sponsor: GE Healthcare

Registration Number: NCT03631771

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy